• Out of 46 papers
• Full list：谷歌学术
• First author (#) / Corresponding author (*)

2024

1. H Wang#, S Zhang#, X Kui, J Ren, X Zhang, W Gao, Y Zhang, H Liu, J Yan, M Sun*, Sijin Wu*, C Wang*, J Yan*, Ciwujianoside E inhibits Burkitt lymphoma cell proliferation and invasion by blocking ENO1-plasminogen interaction and TGF-β1 activation, Biomedicine & Pharmacotherapy, 2024, 177, 116970. DOI: 10.1016/j.biopha.2024.116970
2. L Kong#, F Meng#, P Zhou#, R Ge, X Geng, Z Yang, G Li, L Zhang, J Wang, J Ma, C Dong, J Zhou, Sijin Wu*, D Zhong*, S Xie*, An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer, Science Bulletin, 2024. DOI: 10.1016/j.scib.2024.05.017 

2023

1. Y Fan#, Sijin Wu#, J Shi, X Li, Y Yang, Y Feng*, S Xue*, The catalytic mechanism of direction-dependent interactions for 2, 3-dihydroxybenzoate decarboxylase, Applied Microbiology and Biotechnology, 2023, 107 (24), 7451-7462.
2. Y Liu#, K Yu#, X Kong#, K Zhang, L Wang, N Zhang, Q Chen, M Niu, W Li, X Zhong, Sijin Wu*, J Zhang*, Y Liu*, FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer. Science Advances. 2023, 9 (33), eadg7112.
3. J Bu#, Y Zhang#, Sijin Wu#, H Li#, L Sun#, Y Liu, X Zhu, X Qiao, Q Ma, C Liu, N Niu, J Xue, G Chen, Y Yang*, C Liu*, KK-LC-1 represents a feasible therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer. Nature Communications, 2023, 2602.
4. L Wang#, G Li#, Z Zhou, C Ge, Q Chen, Y Liu, N Zhang, K Zhang, M Niu, W Li, X Zhong, Sijin Wu*, J Zhang*, Y Liu*, Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263. Oncogene, 2023, 1-18.10.1038/s41388-023-02751-1
5. Y Liu#, K Yu#, K Zhang#, M Niu, Q Chen, Y Liu, L Wang, N Zhang, W Li, X Zhong, G Li, Sijin Wu*, J Zhang*, Y Liu*, O-GlcNAcylation elevates TOP2A catalytic activity: a role in the chemoresistance of breast cancer. EMBO Reports. 2023, e56458.
6. L Kong#, F Meng#, Sijin Wu#, P Zhou, R Ge, M Liu, L Zhang, J Zhou, D Zhong*, S Xie*, Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC. Clinical and Translational Medicine, 2023, 13(2): e1191.

2022

1. L Sun#, Y Zhang#, G Chen#, Y Ji#, Q Ma, X Qiao, Sijin Wu*, J Bu, X Zhu, X Zhang, X Jiang, C Liu, X Li, Y Liu, Y Yang, C Liu*, Targeting SOST using a small-molecule compound retards breast cancer bone metastasis. Molecular Cancer, 2022, 21: 228.
2. R Yang, Sijin Wu*, S Wang, G Rubino, JD Nickels, X Cheng*, Refinement of SARS-CoV-2 envelope protein structure in a native-like environment by molecular dynamics simulations. Frontiers in Molecular Biosciences, 2022, 1131.
3. W Su*, Sijin Wu, Y Yang, Y Guo, H Zhang, C Zhang, J Su, L Chen, Z Mao, R Lan, R Cao, C Wang, S Li, M Gao, X Chen, Z Zheng, B Wang, Y Liu, Z Liu, Z Wang, B Liu, X Fan, X Zhang*, Y Guan*, Targeting phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 to treat non-alcoholic steatohepatitis. Nature Communications, 2022, 13(1): 6577.

2021

1. T Li#, L Kong#, X Li, Sijin Wu, K Attri, Y Li, L Herring, J Asara, L Xu, Y Lei, X Cheng, P K Singh, D Green, H Wang*, H Wen*, Mitochondrial calcium signaling facilitates bacterial survival by restraining LC3-associated phagocytosis. Nature Microbiology, 2021, 6, 366.
2. Y Ren#, Sijin Wu#, S Chen, JE Burdette, X Cheng, AD Kinghorn*, Interaction of (+)-Strebloside and Its Derivatives with Na+/K+-ATPase and other targets. Molecules, 2021, 26(18): 5675.
3. Y Ren#, Sijin Wu#, JE Burdette, X Cheng, AD Kinghorn*, Structural insights into the interactions of Digoxin and Na+/K+-ATPase and other targets for the inhibition of cancer cell proliferation. Molecules, 2021, 26(12): 3672.

2020

1. Sijin Wu, C Chan, T Zhuang, PK Li, X Cheng*, A computational study of effects on membrane recruitment of the polar linkers in Vitamin E derivatives. Biochimica et Biophysica Acta - General Subjects, 2020, 1864 (10): 129655.
2. Sijin Wu, X Cheng, Investigation of vitamin E-driven Akt1 membrane recruitment mechanism by molecular simulations. American Chemical Society SciMeetings, 2020 Spring.

2018

1. H Wen#, H Ma#, Q Cai#, S Lin#, B He#, X Lei#, Sijin Wu#, Z Wang, Y Gao, W Liu, W Liu, Q Tao, Z Long, M Yan, K W Kelley, Y Yang*, H Huang*, Q Liu*, Recurrent ECSIT V140A mutation triggers hyperinflammation and promotes hemophagocytic syndrome in NK/T cell lymphoma. Nature Medicine, 2018, 24(2): 154.
2. M Li*#, J Gao#, Y Tang#, M Liu#, Sijin Wu#, K Qu, X Long, H Li, M Liu, Y Liu, J Yuan, L Mao, Y Liu, X Zheng, E Wang, J Wang*, Y Yang*, Traditional herbal medicine-derived sulforaphene LFS-01 reverses colitis in mice by selectively altering the gut microbiota and promoting intestinal gamma-delta T cells. Frontiers in Pharmacology, 2018, 8: 959.

2017

1. X Hu#, Y Cong#, H Luo, Sijin Wu, L Zhao, Q Liu, Y Yang*, Cancer Stem Cells Therapeutic Target Database: the first comprehensive database for therapeutic targets of cancer stem cells. Stem Cells  Translational Medicine, 2017, 6(2): 331.
2. Sijin Wu#, K Zhang#, H Qin, M Niu, W Zhao, M Ye, H Zou, Y Yang*, Caffeic acid phenethyl ester (CAPE) revisited: covalent modulation of XPO1/CRM1 activities and implication for its mechanism of action. Chemical Biology & Drug Design, 2017, 89(5): 655. (Front cover story)

2016

1. Sijin Wu, H Luo, H Wang, W Zhao, Q Hu, Y Yang*, Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors. Biochemical and Biophysical Research Communications, 2016, 478(3): 1268. Link

2015

1. L Cao#, J Zhou#, J Zhang#, Sijin Wu#, X Yang#, X Zhao, H Li, M Luo, Q Yu, G Lin, H Lin, J Xie, P Li, X Hu, C Zheng, G Bu, Y Zhang, H Xu, Y Yang*, C Huang*, J Zhang*, Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clinical Cancer Research, 2015, 21(6): 1419.

2014

1. M Niu#, J Hu#, Sijin Wu#, X Zhang, H Xu, Y Zhang, J Zhang*, Y Yang*, Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE. Chemical Biology & Drug Design, 2014, 83(1): 81.